Ian   Krop, MD, PhD

Ian Krop, MD, PhD

Yale Cancer Center/Smilow Cancer Hospital

Professor of Internal Medicine (Medical Oncology); Associate Cancer Center Director, Clinical Research; Director, Clinical Trials Office; Chief Clinical Research Officer, Yale Cancer Center

Expertise: Medical OncologyDrug DevelopmentClinical TrialsClinical Research

An international leader in the clinical care of patients with breast cancer, Dr. Krop joined Yale from Dana-Farber Cancer Institute where he was the Associate Chief of the Division of Breast Oncology and an Associate Professor of Medicine at Harvard Medical School. Nationally, he serves as Chief Scientific Officer for the Translational Breast Cancer Research Consortium and the Co-Vice Chair for Correlative Science for the Alliance for Clinical Trials in Oncology. His research efforts have advanced the field through clinical trials that define the next generation of therapies for patients. Dr. Krop serves as a member of the NCI Breast Cancer Steering Committee and the Data Monitoring Committee for ECOG/ACRIN. He also serves on the Data and Safety Monitoring Boards for multiple phase III trials.

Education & Training:
PhD-Johns Hopkins University School of Medicine, Biochemistry, Cellular and Molecular Biology
MD-The Johns Hopkins University School of Medicine, Medicine

No Clipping

No Research/Citations

Yale Cancer Center Experts Present New Research at Leading European Oncology Conference

Yale Cancer Center researchers at Yale School of Medicine will present new cancer research at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, October 20 to 24. The annual meeting brings together clinicians, researchers, and patient advocates from all over the world. At ESMO 2023, oncologists will discuss new data and report updates on ongoing studies.
17-Oct-2023 03:05:20 PM EDT

New Study Shows Trastuzumab Deruxtecan Improves Survival for Patients with HER2-positive Metastatic Breast Cancer

A new phase III study has demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive metastatic breast cancer whose cancers were resistant to previous treatment with trastuzumab emtansine. Both trastuzumab deruxtecan and trastuzumab emtansine are antibody-drug conjugates, a relatively new type of drug that delivers chemotherapy directly to the cancer cell, minimizing damage to normal tissues.
03-May-2023 12:00:16 PM EDT

No Quotes

Available for logged-in users onlyLogin HereorRegister

No Video